Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 64.35 as of 2026-10-06T19:46:08.659Z.
Consensus retrieved: 2026-10-06T09:30:31.504Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:46:08.659Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dba20b2ebe204305507788c990a47f536637970c73261bc21f412e79dbf811e
Forward PE Ratio (64.35) = Dated Quote Price ($38.61) / Consensus Forward EPS ($0.60)
FORWARD PE RATIO
64.35
SECTOR MEDIAN · HEALTHCARE
19.80
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+225.00%
vs the sector median at left
BioLife Solutions, Inc.
Market Cap
$1.89B
Forward PE Ratio
64.35
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioLife Solutions, Inc. (BLFS) | $1.89B | 64.35 |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.88B | 24.70 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A |
| Immunome, Inc. (IMNM)vs › | $1.88B | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A |
| Azenta, Inc. (AZTA)vs › | $1.84B | 80.50 |
| AxoGen, Inc. (AXGN)vs › | $1.93B | 81.21 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A |
Trailing P/E
37.7
reported TTM EPS
Forward P/E
64.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.60 implies -41.2% EPS decline vs the reported trailing $1.02.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
At the dated quote price of $38.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.60 | $0.59 – $0.61 | 1 | 64.4x |
| 2027-12-31 | $0.31 | $0.31 – $0.32 | 2 | 123.8x |
| 2028-12-31 | $0.85 | $0.84 – $0.86 | 1 | 45.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
